Загрузка...
BRAF Mutation-selective Inhibition of Thyroid Cancer Cells by the Novel MEK Inhibitor RDEA119 and Genetic-potentiated Synergism with the mTOR Inhibitor Temsirolimus
We examined the therapeutic potential of a novel MEK inhibitor, RDEA119, and its synergism with the mTOR inhibitor temsirolimus in thyroid cancer cell lines. RDEA119 potently inhibited the proliferation of the four cell lines that harbored BRAF mutation, but had no or modest effects on the other fou...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2916062/ https://ncbi.nlm.nih.gov/pubmed/21351275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.25304 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|